This workshop intends to provide an in depth understanding of organizational conflicts of interest and how they impact government acquisitions. Federal agencies must be cognizant organizational conflicts of interest issues throughout the acquisition lifecycle in order to ensure fair competition and that services are performed impartially. As a regulatory agency, FDA encounters some unique organizational conflicts of interest issues due to its relationship with regulated industry. CTP has implemented a robust conflict of interest policy to manage and mitigate potential OCI. This workshop will help support implementation of this policy by providing an in depth understanding of the subject matter. Participants in the workshop will gain an understanding of what an OCI is and why OCI’s matter. They will also learn how to identify and mitigate existing and potential OCIs including best practices and lessons learned. The workshop will include an explanation of legal and regulatory requirements including what the FAR requires, HHS/FDA regulations and non-public information contained in acquisitions settings.
· Learn about the three types of organizational conflicts of interest
· Understand legal and regulatory requirements
· Understand how to identify and evaluate existing OCIs and potential future OCIs
· Understand how to avoid or mitigate existing and potential future OCIs
· Have tools to use to identify and mitigate potential OCIs
· Understand HHS/FDA-specific regulations concerning OCI’s, Standards of Conduct, and FOIA
· Understand the proposed FAR OCI rule
June 8 - 9, 2020 8:30am - 4:30pm WO Building 2, Room 2045 Acquisitions/ COR's - ONLY